- KR₩62bn
- KR₩34bn
- KR₩29bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.85 | ||
| Price to Tang. Book | 0.85 | ||
| Price to Free Cashflow | 20.75 | ||
| Price to Sales | 2.26 | ||
| EV to EBITDA | 10.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.39% | ||
| Return on Equity | 3.32% | ||
| Operating Margin | 1.14% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 30,373.35 | 37,699.31 | 25,179.59 | 26,276.46 | 28,819.03 | n/a | n/a | -24.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.
Directors
- Jae Jin Jang CHM (54)
- Suk Jong Choi VCH (50)
- Yeong Cheol Shin VPR (63)
- Ju Min Kim VPR (49)
- Sang Nyeon Kim VPR (52)
- Jae Gu Choi OTH (54)
- Gang Mun Choi DRC (47)
- No Hyeon Sung NID (54)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 16th, 1959
- Public Since
- December 28th, 1976
- No. of Shareholders
- 25,800
- No. of Employees
- 126
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 118,568,126
- Address
- 322, Galmachi-ro, Jungwon-gu, SEONGNAM, 13201
- Web
- https://www.orientbio.co.kr/
- Phone
- +82 317306000
- Auditors
- LIAN Accounting Corporation
Upcoming Events for 002630
Similar to 002630
Celltrion
Korea Exchange - KSE
Gene One Life Science
Korea Exchange - KSE
FAQ
What is the Orient Bio share price?
As of Today at 19:16 UTC, shares in Orient Bio are trading at KR₩525. This share price information is delayed by 15 minutes.
How has the Orient Bio share price performed this year?
Shares in Orient Bio last closed at KR₩525 and the price had moved by -14.19% over the past 365 days. In terms of relative price strength the Orient Bio share price has underperformed the FTSE Developed Asia Pacific Index by -14.11% over the past year.
What are the analyst and broker recommendations for Orient Bio?
There is no consensus recommendation for this security.
What is the Orient Bio dividend yield?
Orient Bio does not currently pay a dividend.
Does Orient Bio pay a dividend?
Orient Bio does not currently pay a dividend.
When does Orient Bio next pay dividends?
Orient Bio does not currently pay a dividend.
How do I buy Orient Bio shares?
To buy shares in Orient Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orient Bio?
As of the previous close price of KR₩525, shares in Orient Bio had a market capitalisation of KR₩62bn.
Where are Orient Bio shares listed?
Here are the trading details for Orient Bio:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 002630
What kind of share is Orient Bio?
Based on an overall assessment of its quality, value and momentum Orient Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orient Bio share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Orient Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orient Bio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.03%.
As of the last closing price of KR₩525, shares in Orient Bio were trading -13.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orient Bio PE Ratio?
The Orient Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩525.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orient Bio?
Orient Bio's management team is headed by:
- Jae Jin Jang - CHM
- Suk Jong Choi - VCH
- Yeong Cheol Shin - VPR
- Ju Min Kim - VPR
- Sang Nyeon Kim - VPR
- Jae Gu Choi - OTH
- Gang Mun Choi - DRC
- No Hyeon Sung - NID